Status:
COMPLETED
Study Evaluating MYO-029 in Adult Muscular Dystrophy
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Becker Muscular Dystrophy
Facioscapulohumeral Muscular Dystrophy
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this phase I/II, multicenter, safety trial is to study MYO-029 in adult patients with muscular dystrophy.
Eligibility Criteria
Inclusion
- Written informed consent.
- Confirmed clinical and molecular diagnosis of Becker Muscular Dystrophy (BMD), Facioscapulohumeral Muscular Dystrophy (FSHD), or Limb-Girdle Muscular Dystrophy (LGMD)
- Independently ambulatory
Exclusion
- Patients with certain clinical conditions
- Patients using steroids or other medications with the potential to affect muscle function
- History of sensitivity to monoclonal antibodies or protein pharmaceuticals
- Pregnant or lactating women.
Key Trial Info
Start Date :
February 1 2005
Trial Type :
INTERVENTIONAL
End Date :
January 1 2007
Estimated Enrollment :
108 Patients enrolled
Trial Details
Trial ID
NCT00104078
Start Date
February 1 2005
End Date
January 1 2007
Last Update
December 28 2007
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Washington D.C., District of Columbia, United States, 20010
2
Kansas City, Kansas, United States
3
Baltimore, Maryland, United States, 21287-7519
4
Boston, Massachusetts, United States